- Home
- RDVT vs KURA Comparison
RDVT vs KURA Comparison
Compare RDVT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- KURA
- Stock Information
- Founded
- RDVT 2017
- KURA 2014
- Country
- RDVT United States
- KURA United States
- Employees
- RDVT N/A
- KURA N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDVT Technology
- KURA Health Care
- Exchange
- RDVT Nasdaq
- KURA Nasdaq
- Market Cap
- RDVT 606.7M
- KURA 713.5M
- IPO Year
- RDVT N/A
- KURA N/A
- Fundamental
- Price
- RDVT $48.99
- KURA $8.31
- Analyst Decision
- RDVT
- KURA Buy
- Analyst Count
- RDVT 0
- KURA 14
- Target Price
- RDVT N/A
- KURA $24.45
- AVG Volume (30 Days)
- RDVT 96.2K
- KURA 1.9M
- Earning Date
- RDVT 11-05-2025
- KURA 11-06-2025
- Dividend Yield
- RDVT 0.61%
- KURA N/A
- EPS Growth
- RDVT N/A
- KURA N/A
- EPS
- RDVT 0.61
- KURA N/A
- Revenue
- RDVT $82,399,000.00
- KURA $83,279,000.00
- Revenue This Year
- RDVT $19.34
- KURA $60.25
- Revenue Next Year
- RDVT $13.60
- KURA $155.10
- P/E Ratio
- RDVT $79.69
- KURA N/A
- Revenue Growth
- RDVT 22.14
- KURA N/A
- 52 Week Low
- RDVT $25.37
- KURA $5.41
- 52 Week High
- RDVT $54.19
- KURA $21.40
- Technical
- Relative Strength Index (RSI)
- RDVT 54.58
- KURA 60.21
- Support Level
- RDVT $47.13
- KURA $8.09
- Resistance Level
- RDVT $51.47
- KURA $8.90
- Average True Range (ATR)
- RDVT 1.82
- KURA 0.50
- MACD
- RDVT -0.16
- KURA -0.02
- Stochastic Oscillator
- RDVT 26.27
- KURA 54.92
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.